BR112018072039A2 - composto, medicamento, método, e, uso do composto ou sal do mesmo - Google Patents

composto, medicamento, método, e, uso do composto ou sal do mesmo

Info

Publication number
BR112018072039A2
BR112018072039A2 BR112018072039-9A BR112018072039A BR112018072039A2 BR 112018072039 A2 BR112018072039 A2 BR 112018072039A2 BR 112018072039 A BR112018072039 A BR 112018072039A BR 112018072039 A2 BR112018072039 A2 BR 112018072039A2
Authority
BR
Brazil
Prior art keywords
compound
salt
drug
formula
symbol
Prior art date
Application number
BR112018072039-9A
Other languages
English (en)
Other versions
BR112018072039B1 (pt
Inventor
Kawakita Youichi
Kojima Takuto
Nii Noriyuki
Ito Yoshiteru
Sakauchi Nobuki
Banno Hiroshi
Liu Xin
Ono Koji
Imamura Keisuke
Imamura Shinichi
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of BR112018072039A2 publication Critical patent/BR112018072039A2/pt
Publication of BR112018072039B1 publication Critical patent/BR112018072039B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

é fornecido um composto, ou um sal do mesmo, representado pela fórmula (i): [na fórmula cada símbolo é como definido na descrição da presente invenção].
BR112018072039-9A 2016-04-28 2017-04-27 Composto, medicamento, e, uso do composto ou sal do mesmo BR112018072039B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016-091717 2016-04-28
JP2016091717 2016-04-28
PCT/JP2017/016717 WO2017188374A1 (ja) 2016-04-28 2017-04-27 縮合複素環化合物

Publications (2)

Publication Number Publication Date
BR112018072039A2 true BR112018072039A2 (pt) 2019-02-12
BR112018072039B1 BR112018072039B1 (pt) 2023-12-26

Family

ID=60159711

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018072039-9A BR112018072039B1 (pt) 2016-04-28 2017-04-27 Composto, medicamento, e, uso do composto ou sal do mesmo

Country Status (19)

Country Link
US (3) US10577382B2 (pt)
EP (1) EP3450436B1 (pt)
JP (2) JP6924182B2 (pt)
KR (1) KR102431405B1 (pt)
CN (1) CN109415384B (pt)
BR (1) BR112018072039B1 (pt)
CA (1) CA3021185A1 (pt)
DK (1) DK3450436T3 (pt)
EA (1) EA039529B1 (pt)
ES (1) ES2927529T3 (pt)
HR (1) HRP20221277T1 (pt)
HU (1) HUE059954T2 (pt)
LT (1) LT3450436T (pt)
MA (1) MA44781B1 (pt)
PL (1) PL3450436T3 (pt)
PT (1) PT3450436T (pt)
RS (1) RS63656B1 (pt)
SG (2) SG10201912270PA (pt)
WO (1) WO2017188374A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA039529B1 (ru) 2016-04-28 2022-02-07 Такеда Фармасьютикал Компани Лимитед Конденсированные гетероциклические соединения
CN113773247A (zh) * 2021-07-23 2021-12-10 无锡海伦生物科技有限公司 一种2-氨基-5-碘吡啶的制备方法
WO2023190967A1 (ja) * 2022-03-31 2023-10-05 Ｃｈｏｒｄｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 イミダゾ［４，５－ｂ］ピリジン誘導体による固形癌治療のためのバイオマーカー
CN115006411A (zh) * 2022-07-26 2022-09-06 中南大学湘雅医院 依拉环素类化合物的应用、药物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2331640C2 (ru) * 1999-05-21 2008-08-20 Бристол-Маерс Сквибб Ко. Пирролтриазиновые ингибиторы киназ
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
AU2009278442B2 (en) * 2008-08-05 2013-09-26 Daiichi Sankyo Company, Limited Imidazopyridin-2-one Derivatives
EP2464231A4 (en) * 2009-08-10 2013-02-06 Samumed Llc INDAZOLE AS WNT / B-CATENINE SIGNALING PATHWASHER AND THERAPEUTIC APPLICATIONS THEREOF
CA2770116C (en) * 2009-08-10 2018-03-13 Epitherix, Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
US20130165426A1 (en) 2010-07-06 2013-06-27 Université de Montréal Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
EA039529B1 (ru) * 2016-04-28 2022-02-07 Такеда Фармасьютикал Компани Лимитед Конденсированные гетероциклические соединения

Also Published As

Publication number Publication date
EA039529B1 (ru) 2022-02-07
CN109415384A (zh) 2019-03-01
US10577382B2 (en) 2020-03-03
JPWO2017188374A1 (ja) 2019-02-28
SG11201809243YA (en) 2018-11-29
EP3450436A4 (en) 2019-10-30
KR20190002547A (ko) 2019-01-08
ES2927529T3 (es) 2022-11-08
CN109415384B (zh) 2022-01-11
EP3450436A1 (en) 2019-03-06
PL3450436T3 (pl) 2022-12-27
MA44781A (fr) 2019-03-06
RS63656B1 (sr) 2022-11-30
US20210115067A1 (en) 2021-04-22
JP2021176901A (ja) 2021-11-11
EP3450436B1 (en) 2022-07-27
LT3450436T (lt) 2022-09-12
KR102431405B1 (ko) 2022-08-10
JP7130098B2 (ja) 2022-09-02
SG10201912270PA (en) 2020-02-27
CA3021185A1 (en) 2017-11-02
HRP20221277T1 (hr) 2022-12-23
EA201892449A1 (ru) 2019-05-31
PT3450436T (pt) 2022-09-29
WO2017188374A1 (ja) 2017-11-02
US20190106437A1 (en) 2019-04-11
MA44781B1 (fr) 2022-10-31
US20200140462A1 (en) 2020-05-07
BR112018072039B1 (pt) 2023-12-26
US11390634B2 (en) 2022-07-19
JP6924182B2 (ja) 2021-08-25
DK3450436T3 (da) 2022-09-12
US10981934B2 (en) 2021-04-20
HUE059954T2 (hu) 2023-01-28

Similar Documents

Publication Publication Date Title
BR112018073384A2 (pt) polinucleotídeos moduladores
BR112017006253A2 (pt) novos compostos
BR112016024545A2 (pt) derivados de pirazolo pirimidina e seu uso como inibidores de malt1
BR112017008659A2 (pt) ?métodos e compostos de agonista de gip?
BR112017006240A2 (pt) novos compostos
BR112015032539A2 (pt) compostos ureia tricíclicos fundidos como inibidores de raf cinase e/ou dímero de raf cinase
BR112016006319A2 (pt) inibidores de irak e usos dos mesmos
BR112016029825A2 (pt) composto
BR112016007396A2 (pt) derivados de cetona pirídicos, método de preparação dos mesmos e aplicação farmacêutica dos mesmos
BR112016017317A2 (pt) composto, antagonista de trpa1, medicamento, e, uso de um composto
BR112016011755A2 (pt) derivado de ureia ou sal farmacologicamente aceitável do mesmo
BR112017009470A2 (pt) síntese de copanlisib e seu sal de di-hidrocloreto.
BR112015021524A2 (pt) derivados de sulfonil quinolina e usos dos mesmos
BR112015004029A2 (pt) Processo para preparação de teneligliptina, de um composto ou de sal ou hidrato do mesmo
BR112018072039A2 (pt) composto, medicamento, método, e, uso do composto ou sal do mesmo
BR112017010471A2 (pt) compostos de di-hidropirimidin-2-ona e usos médicos dos mesmos
BR112018000187A2 (pt) composto, composição, método, e, uso de um composto ou composição
GT201700058A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
BR112017018834A2 (pt) variantes de protoxina-ii e métodos de uso
BR112016027691A2 (pt) Composto de tetra-hidropiridopirimidina e seus usos
BR112018003331A2 (pt) sondas para imagear proteína huntingtina
BR112017004136A2 (pt) sondas para imageamento de proteína de huntingtina
BR112016007062A2 (pt) variantes de protoxina-ii e métodos de uso
BR112018005795A2 (pt) inibidor de quinase de egfr e método de preparação e seu uso
BR112018008006A2 (pt) composto de piranodipiridina

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/04/2017, OBSERVADAS AS CONDICOES LEGAIS